{"gene":"PLCG2","run_date":"2026-04-28T19:45:44","timeline":{"discoveries":[{"year":2012,"finding":"In-frame genomic deletions within a region encoding an autoinhibitory domain of PLCγ2 result in protein products with constitutive phospholipase activity; these deletion proteins show diminished cellular signaling at 37°C but enhanced signaling at subphysiologic temperatures, establishing a temperature-sensitive gain-of-function mechanism underlying PLAID.","method":"Genomic sequencing, cDNA sequencing, enzymatic assays, flow cytometry, lymphocyte stimulation assays","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (sequencing, enzymatic assay, cellular signaling) in a single rigorous study with functional validation","pmids":["22236196"],"is_preprint":false},{"year":2012,"finding":"The p.Ser707Tyr substitution in the autoinhibitory SH2 domain of PLCγ2 causes a hypermorphic gain-of-function, leading to enhanced PLCγ2 activity and increased intracellular signaling at physiological temperatures, distinct from the cold-sensitive PLAID deletions.","method":"Whole-exome sequencing, overexpression of mutant protein in heterologous cells, ex vivo leukocyte signaling assays","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 — reciprocal functional assays (overexpression + ex vivo) with multiple orthogonal methods","pmids":["23000145"],"is_preprint":false},{"year":2015,"finding":"The APLAID-causing hypermorphic PLCγ2 p.Ser707Tyr mutation causes elevated basal intracellular Ca2+ and enhanced Ca2+ flux, which activates the NLRP3 inflammasome, linking PLCγ2-mediated Ca2+ signaling to IL-1β secretion and sterile inflammation; this effect was attenuated by PLC inhibitors, intracellular Ca2+ blockers, or adenylate cyclase activators.","method":"Western blotting (inflammasome activation), FLIPR calcium flux assay, pharmacological inhibition in patient PBMCs","journal":"Arthritis & rheumatology (Hoboken, N.J.)","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, functional rescue experiments in patient-derived cells","pmids":["25418813"],"is_preprint":false},{"year":2019,"finding":"The PLCG2 p.P522R (Pro522Arg) variant is a functional hypermorph that weakly increases PLCγ2 enzymatic activity, as demonstrated by radioactive phospholipase assay, IP-One ELISA, and calcium assays in heterologous COS7 and HEK293T cells.","method":"Radioactive enzymatic assay, IP-One ELISA, calcium assay in transfected COS7 and HEK293T cells","journal":"Alzheimer's research & therapy","confidence":"High","confidence_rationale":"Tier 1 — three orthogonal in vitro assays in a single study with rigorous controls","pmids":["30711010"],"is_preprint":false},{"year":2019,"finding":"A novel gain-of-function mutation in the C2 domain of PLCγ2 (p.Met1141Lys) causes platelet hyper-reactivity, increased BCR-triggered calcium influx and ERK phosphorylation, and enhanced BCR-triggered influx of external calcium in a PLCγ2-knockout DT40 cell line, demonstrating that the C2 domain can regulate PLCγ2 autoinhibition.","method":"Flow cytometry (calcium flux, ERK phosphorylation), DT40 knockout cell overexpression system, platelet function assay","journal":"Journal of clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays in knockout reconstitution system, single lab","pmids":["31853824"],"is_preprint":false},{"year":2020,"finding":"Novel APLAID-causing PLCG2 variants (p.Ala708Pro and p.Leu845_Leu848del) activate the NLRP3 inflammasome through the alternative pathway (not the canonical pathway), as demonstrated by ex vivo calcium responses of patient B cells and in vitro PLC activity assays.","method":"Ex vivo B cell calcium flux assay, in vitro PLC activity assay, inflammasome pathway analysis","journal":"Journal of clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional validation with multiple assays, single lab","pmids":["32671674"],"is_preprint":false},{"year":2018,"finding":"The novel APLAID-causing p.Leu848Pro mutation in PLCγ2 (located in the cSH2 domain) leads to increased basal and EGF-stimulated PLCγ2 activity in vitro, expanding the spectrum of gain-of-function PLCG2 mutations affecting the autoinhibitory domain.","method":"In vitro PLC activity assay, whole blood cytokine assays","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro activity assay with functional follow-up, single lab","pmids":["30619256"],"is_preprint":false},{"year":2023,"finding":"PLCG2 variants functionally classified as gain-of-function (GOF) or monoallelic loss-of-function (LOF) alter B-cell activation (BCR-induced calcium flux and ERK phosphorylation) in opposite directions; monoallelic LOF variants define a new class associated with humoral immune deficiency, autoinflammation, herpesvirus susceptibility, and NK cell dysfunction.","method":"Mutagenesis of EGFP-PLCG2 plasmid, overexpression in Plcg2-deficient DT40 B cells, flow cytometry (calcium flux, ERK phosphorylation), primary patient cell stimulation","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 — systematic functional classification using knockout reconstitution + primary cells, multiple variants tested","pmids":["37769878"],"is_preprint":false},{"year":2023,"finding":"PLCγ2 haploinsufficiency (loss-of-function heterozygous PLCG2 variants) impairs NK cell calcium flux and cytotoxicity while preserving B-cell function, establishing a distinct NK cell immunodeficiency syndrome; this phenotype was recapitulated in Plcg2+/- mice.","method":"Whole-exome sequencing, mass cytometry, functional assays (calcium flux, cytotoxicity), Plcg2+/- mouse model","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 — human and mouse data with multiple orthogonal functional assays, phenotype replicated in mouse model","pmids":["37714437"],"is_preprint":false},{"year":2020,"finding":"Rh-CSF1 activates a CSF1R/PLCG2/PKA/UCP2 signaling pathway in neonatal rat brain after hypoxic-ischemic injury, reducing oxidative stress and neuronal apoptosis; pharmacological inhibition of PLCG2 with U73122 abolished the neuroprotective effects of rh-CSF1.","method":"Western blot (p-PLCG2, p-PKA, UCP2), pharmacological inhibition (BLZ945, U73122), immunofluorescence, behavioral tests, TUNEL/Fluoro-Jade staining in rat HI model","journal":"Oxidative medicine and cellular longevity","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological epistasis with pathway readout, in vivo model, single lab","pmids":["33101590"],"is_preprint":false},{"year":2020,"finding":"Rh-CSF1 activates a CSF1R/PLCG2/PKCε/CREB signaling axis that attenuates neuroinflammation after hypoxic-ischemia; inhibition of PLCG2 with U73122 blocked the anti-inflammatory effects including IL-1β and TNF-α downregulation.","method":"Western blot (p-PLCG2, p-PKCε, p-CREB), pharmacological inhibition, immunofluorescence, rat HI model","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological epistasis establishing pathway position, in vivo model, single lab","pmids":["32522286"],"is_preprint":false},{"year":2025,"finding":"PLCG2 deficiency in 5xFAD mice reduces TREM2 expression and impairs microglial association with amyloid-beta plaques, while TREM2 deficiency increases PLCG2 expression; human transcriptomics confirmed a positive correlation between PLCG2 and TREM2 expression independent of pathological scores, indicating PLCG2 acts upstream to regulate TREM2-mediated immune responses.","method":"5xFAD x PLCG2-KO x TREM2-KO mouse crosses, RNA-sequencing (mouse and human bulk), immunostaining","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with orthogonal human and mouse data, double-KO cross design","pmids":["40346446"],"is_preprint":false},{"year":2024,"finding":"The novel PLCγ2 D993Y variant (APLAID-associated) disrupts the interaction between the catalytic and autoinhibitory domains of PLCγ2, causing autoactivation with heightened PLCγ2 phosphorylation, elevated IP3 production, increased intracellular Ca2+ release, and activation of MAPK, NF-κB, and NFAT signaling pathways.","method":"Immunoblotting, luciferase assay (NF-κB/NFAT), inositol monophosphate ELISA, calcium flux assay, immunoprecipitation (domain interaction), overexpression in HEK293T/COS-7/THP-1 KO cells","journal":"Arthritis & rheumatology (Hoboken, N.J.)","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal mechanistic assays including domain interaction by Co-IP and functional reconstitution in KO cells","pmids":["38965708"],"is_preprint":false},{"year":2022,"finding":"The protective PLCG2-P522R variant in human iPSC-derived microglia transplanted into chimeric AD mice induces significant upregulation of HLA expression and antigen presentation, chemokine signaling, and T cell proliferation pathways, and promotes CD8+ T cell recruitment to the brain.","method":"Chimeric mouse model with iPSC-microglia transplantation, single-cell and bulk RNA sequencing, histological analysis","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","confidence":"High","confidence_rationale":"Tier 2 — iPSC-microglia chimeric mouse model with scRNA-seq, strong functional readout","pmids":["35142046"],"is_preprint":false},{"year":2022,"finding":"PLCG2 expression in microglia is induced by amyloid plaques in a disease progression-dependent manner in 5xFAD mice, and PLCG2 co-expression network analysis links PLCG2 to inflammatory pathways including NF-κB signaling and response to LPS; inactivation of Plcg2 in mice altered immune-related gene expression without changing microglial cell coverage or morphology.","method":"Bulk RNA-seq (human AD brain, 5xFAD mice), single-cell RNA-seq, microglia depletion, immunostaining, differential expression analysis in Plcg2-inactivated mice","journal":"Genome medicine","confidence":"Medium","confidence_rationale":"Tier 2 — multiple transcriptomic datasets + mouse model with KO validation, single primary analysis","pmids":["35180881"],"is_preprint":false},{"year":2025,"finding":"Risk-conferring PLCG2-M28L microglia (iPSC-derived) share transcriptomic similarity with PLCG2-KO microglia, showing reduced TREM2 expression, blunted inflammatory responses, and increased proliferation/cell death, whereas protective PLCG2-P522R microglia show elevated cytokine secretion after LPS and resistance to apoptosis, demonstrating that PLCG2 variants bidirectionally modulate microglial immune state and function.","method":"iPSC-derived microglia with isogenic PLCG2 variants (P522R, M28L, KO), bulk transcriptomics, flow cytometry, cytokine assays, apoptosis assays","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","confidence":"High","confidence_rationale":"Tier 2 — isogenic iPSC model with multiple variants, multiple orthogonal functional assays","pmids":["41066163"],"is_preprint":false},{"year":2024,"finding":"The DNMT3B methyltransferase inhibits PLCG2 transcription by methylating the PLCG2 promoter region in colorectal cancer cells; overexpression of PLCG2 suppresses colorectal cancer xenograft tumor growth in vivo.","method":"Methylation-specific PCR (MSP), bisulfite-sequencing PCR (BSP), DNMT3B overexpression/knockdown, PLCG2 overexpression, xenograft mouse model","journal":"Acta biochimica et biophysica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 — direct epigenetic mechanism (MSP/BSP) + in vivo functional validation, single lab","pmids":["39108206"],"is_preprint":false},{"year":2025,"finding":"A novel PLCG2 mRNA isoform (D65-PLCG2) lacking 65 bp from exon 28 is susceptible to nonsense-mediated decay and lacks Ca2+ responsiveness (demonstrated in transfected HEK293 cells); the rs1071644-T allele promotes increased exon 28 skipping via a functional splicing variant, thereby reducing functional PLCγ2 and increasing AD risk.","method":"Minigene splicing assay in BV-2 microglial cells, cycloheximide NMD assay, HEK293 transfection calcium assay, qRT-PCR in human brain/buffy coat","journal":"Molecular neurodegeneration advances","confidence":"Medium","confidence_rationale":"Tier 1-2 — functional minigene assay + calcium assay + NMD validation, single lab","pmids":["41459197"],"is_preprint":false},{"year":2025,"finding":"PLCγ2 mediates spontaneous calcium oscillation and chemoattractant-induced calcium response in neutrophils; PLCγ2 knockdown impairs spontaneous Ca2+ oscillation, reduces membrane targeting of CAPRI (a RasGAP), causes increased Ras/PI3Kγ activation and actin polymerization, and alters the chemoattractant concentration range for neutrophil chemotaxis.","method":"plcg2 knockdown neutrophils, calcium imaging, membrane targeting assays, PI3K activity, actin polymerization assays, chemotaxis assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with multiple pathway readouts; preprint, not peer-reviewed","pmids":["bio_10.1101_2025.04.07.647573"],"is_preprint":true},{"year":2024,"finding":"PLCG2 in colorectal cancer cells promotes proliferation, invasion, metastasis, EMT, and cell cycle progression while inhibiting apoptosis via Akt-mTOR pathway activation; PLCG2 knockdown also suppresses CD8+ T cell infiltration, promotes Treg infiltration, and upregulates PD-1/PD-L1 expression, potentiating immune checkpoint blockade therapy.","method":"RNA-seq, western blotting, qRT-PCR, in vivo xenograft models, flow cytometry, multiplex immunohistochemistry","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo loss-of-function with defined pathway (Akt-mTOR) and immune microenvironment readouts, single lab","pmids":["39494327"],"is_preprint":false},{"year":2024,"finding":"Splice site mutations and de novo deletions in PLCG2 can cause in-frame exon skipping (e.g., loss of exons 18-19 or 19-22); overexpression of these deletion transcripts in Plcg2-deficient DT40 cells failed to phosphorylate ERK in response to BCR crosslinking, confirming dominant-negative function at physiological temperature.","method":"Full-length PLCG2 cDNA RNA sequencing, whole genome sequencing, DT40 Plcg2-KO overexpression, flow cytometry (ERK phosphorylation)","journal":"The Journal of allergy and clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 — knockout reconstitution system with BCR signaling readout, validated with primary patient samples","pmids":["39667583"],"is_preprint":false},{"year":1995,"finding":"The PLCG2 gene was mapped to chromosome 16q22-qter in humans and to the central region of mouse chromosome 8, establishing that PLCG2 and PLCG1 are members of a dispersed gene family mapping to distinct chromosomal regions.","method":"Interspecific backcross mapping (mouse), rodent/human somatic cell hybrid panel (human)","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — direct chromosomal mapping with two orthogonal approaches","pmids":["7774933"],"is_preprint":false}],"current_model":"PLCγ2 is a phospholipase C enzyme that hydrolyzes phosphatidylinositol 4,5-bisphosphate to generate IP3 and diacylglycerol, thereby releasing intracellular Ca2+ and activating downstream signaling (PKC, MAPK, NF-κB, NFAT); its activity is kept in check by an autoinhibitory SH2 domain, such that in-frame deletions or missense mutations disrupting this domain cause gain-of-function (constitutive or temperature-sensitive activity) driving PLAID/APLAID immune dysregulation, whereas haploinsufficiency impairs NK cell calcium flux and cytotoxicity; in microglia, PLCγ2 acts downstream of CSF1R and upstream of TREM2 to regulate microglial phagocytic and inflammatory responses to amyloid pathology, and in neutrophils it controls spontaneous calcium oscillation, membrane targeting of the RasGAP CAPRI, and chemotaxis sensitivity."},"narrative":{"teleology":[{"year":1995,"claim":"Establishing that PLCG2 is a distinct gene family member at chromosome 16q22 resolved its genomic identity relative to PLCG1 and enabled subsequent mutation-phenotype studies.","evidence":"Interspecific backcross mapping and somatic cell hybrid panel analysis in mouse and human","pmids":["7774933"],"confidence":"Medium","gaps":["No functional data from mapping alone","Expression pattern across tissues not determined"]},{"year":2012,"claim":"Discovery that in-frame deletions in the autoinhibitory cSH2 domain cause constitutive phospholipase activity with temperature-sensitive signaling established the first molecular mechanism for PLAID and identified the autoinhibitory domain as the key regulatory element of PLCγ2.","evidence":"Genomic/cDNA sequencing, enzymatic assays, and lymphocyte signaling in PLAID patient cells","pmids":["22236196"],"confidence":"High","gaps":["Structural basis of temperature sensitivity not resolved","Whether other domain mutations can cause similar phenotypes was unknown"]},{"year":2012,"claim":"Identification of the p.Ser707Tyr missense mutation as a constitutive gain-of-function at physiological temperature distinguished APLAID from the cold-sensitive PLAID mechanism, showing that different classes of autoinhibitory disruption produce distinct clinical syndromes.","evidence":"Whole-exome sequencing, overexpression in heterologous cells, and ex vivo leukocyte signaling","pmids":["23000145"],"confidence":"High","gaps":["Structural mechanism by which S707Y disrupts autoinhibition not defined","Downstream inflammatory consequences not yet explored"]},{"year":2015,"claim":"Linking the PLCγ2 S707Y gain-of-function to NLRP3 inflammasome activation via elevated basal Ca²⁺ established the signaling chain from PLCγ2 hyperactivity to IL-1β-mediated sterile inflammation, explaining APLAID pathogenesis.","evidence":"FLIPR calcium flux, inflammasome western blot, and pharmacological rescue (PLC inhibitors, Ca²⁺ blockers) in patient PBMCs","pmids":["25418813"],"confidence":"High","gaps":["Whether canonical vs. alternative inflammasome pathway is engaged was unresolved","Contribution of DAG/PKC arm to inflammasome activation not dissected"]},{"year":2018,"claim":"Expanding the mutational spectrum to include p.Leu848Pro in the cSH2 domain confirmed that multiple positions within the autoinhibitory region regulate PLCγ2 basal activity.","evidence":"In vitro PLC activity assay and whole blood cytokine assays","pmids":["30619256"],"confidence":"Medium","gaps":["Only a single variant tested","No structural modeling of how L848P disrupts autoinhibition"]},{"year":2019,"claim":"Demonstrating that the AD-protective P522R variant is a weak enzymatic hypermorph connected PLCγ2 gain-of-function to neuroprotection and positioned PLCγ2 as a modulator of microglial function in neurodegeneration.","evidence":"Radioactive phospholipase assay, IP-One ELISA, and calcium assay in transfected COS7/HEK293T cells","pmids":["30711010"],"confidence":"High","gaps":["Mechanism of P522R-mediated neuroprotection in microglia not yet characterized","Whether enzymatic hyperactivity alone explains the protective effect was unclear"]},{"year":2019,"claim":"Discovery that the C2 domain mutation p.Met1141Lys causes gain-of-function revealed a second autoinhibitory surface beyond the cSH2 domain, broadening understanding of PLCγ2 regulation.","evidence":"Calcium flux and ERK phosphorylation in PLCγ2-knockout DT40 cell reconstitution system","pmids":["31853824"],"confidence":"Medium","gaps":["Only one C2-domain variant tested","No direct biophysical evidence of C2–catalytic domain interaction"]},{"year":2020,"claim":"Placing PLCγ2 downstream of CSF1R in a CSF1R/PLCγ2/PKA/UCP2 and CSF1R/PLCγ2/PKCε/CREB signaling axis in neonatal brain defined PLCγ2's role in anti-oxidative and anti-inflammatory neuroprotection.","evidence":"Pharmacological epistasis (U73122, BLZ945) with western blot pathway readouts in rat hypoxic-ischemic injury model","pmids":["33101590","32522286"],"confidence":"Medium","gaps":["Reliance on U73122, a non-specific PLC inhibitor","No genetic confirmation in PLCγ2-deficient animals","Single lab, single model system"]},{"year":2020,"claim":"Showing that novel APLAID variants activate the alternative (not canonical) NLRP3 inflammasome pathway refined the inflammatory mechanism downstream of PLCγ2 hyperactivity.","evidence":"Ex vivo B cell calcium flux and in vitro PLC activity assays in patient cells","pmids":["32671674"],"confidence":"Medium","gaps":["Distinction between canonical and alternative inflammasome activation requires further biochemical dissection","Single lab"]},{"year":2022,"claim":"Demonstrating that P522R microglia transplanted into AD mice upregulate HLA, antigen presentation, and CD8⁺ T cell recruitment established a cell-autonomous immune-enhancing mechanism for the protective PLCγ2 variant in Alzheimer's disease.","evidence":"iPSC-derived microglia chimeric mouse model with scRNA-seq and histological analysis","pmids":["35142046"],"confidence":"High","gaps":["Whether enhanced antigen presentation is sufficient for neuroprotection not tested","Chimeric model may not fully recapitulate endogenous microglial function"]},{"year":2022,"claim":"Showing that PLCγ2 expression in microglia is induced by amyloid plaques in a progression-dependent manner and that inactivation alters immune gene expression linked PLCγ2 to disease-stage-specific microglial inflammatory programs.","evidence":"Bulk and single-cell RNA-seq in human AD brain and 5xFAD mice, Plcg2-inactivated mouse model","pmids":["35180881"],"confidence":"Medium","gaps":["Transcriptomic changes without demonstration of phagocytic or clearance phenotype","Mechanism of plaque-dependent induction of PLCG2 not identified"]},{"year":2023,"claim":"Systematic functional classification of GOF and LOF PLCG2 variants in DT40 reconstitution and patient cells revealed that monoallelic LOF defines a new class of immune deficiency, establishing a bidirectional genotype-phenotype framework.","evidence":"Mutagenesis, Plcg2-deficient DT40 overexpression, flow cytometry for calcium/ERK, primary patient cell stimulation","pmids":["37769878"],"confidence":"High","gaps":["Not all variants tested in primary human cells","In vivo consequences of LOF variants in adaptive immunity not fully explored"]},{"year":2023,"claim":"Establishing that PLCγ2 haploinsufficiency selectively impairs NK cell calcium flux and cytotoxicity (but not B cell function) identified a cell-type-specific dependency and a distinct NK cell immunodeficiency phenotype, replicated in Plcg2⁺/⁻ mice.","evidence":"Whole-exome sequencing, mass cytometry, functional assays, Plcg2⁺/⁻ mouse model","pmids":["37714437"],"confidence":"High","gaps":["Mechanism of selective NK cell vulnerability versus B cell resilience not explained","Threshold of PLCγ2 activity required for NK function unknown"]},{"year":2024,"claim":"Structural-functional analysis of the D993Y variant demonstrated direct disruption of catalytic-autoinhibitory domain interaction, causing autoactivation of IP3/Ca²⁺/MAPK/NF-κB/NFAT, providing the most detailed intramolecular mechanism for PLCγ2 autoinhibition relief.","evidence":"Co-IP of domain interactions, IP1 ELISA, calcium flux, NF-κB/NFAT luciferase reporters in THP-1 KO and HEK293T cells","pmids":["38965708"],"confidence":"High","gaps":["No crystal structure of autoinhibited vs. activated PLCγ2","Mechanism applicable to all GOF variants not confirmed"]},{"year":2024,"claim":"Splice-site mutations causing in-frame exon skipping produced dominant-negative PLCγ2 proteins that failed to activate ERK upon BCR crosslinking, expanding the LOF variant class beyond point mutations.","evidence":"Full-length cDNA RNA-seq, WGS, DT40 Plcg2-KO reconstitution with flow cytometry","pmids":["39667583"],"confidence":"Medium","gaps":["Dominant-negative mechanism (e.g., competition for scaffolding) not biochemically defined","Limited number of splice variants tested"]},{"year":2025,"claim":"Genetic epistasis in 5xFAD mice showed PLCγ2 deficiency reduces TREM2 expression and microglial plaque association while TREM2 deficiency increases PLCγ2, establishing PLCγ2 as an upstream positive regulator of TREM2 with a feedback loop.","evidence":"5xFAD × PLCG2-KO × TREM2-KO crosses, RNA-seq (mouse and human), immunostaining","pmids":["40346446"],"confidence":"High","gaps":["Direct biochemical mechanism linking PLCγ2 activity to TREM2 transcription unknown","Whether the feedback loop operates in non-AD contexts not tested"]},{"year":2025,"claim":"Isogenic iPSC-microglia carrying P522R versus M28L versus KO demonstrated bidirectional modulation of microglial immune state: P522R enhances cytokine secretion and resists apoptosis while M28L/KO show blunted responses and reduced TREM2, consolidating the variant-function spectrum in a disease-relevant cell type.","evidence":"Isogenic iPSC-derived microglia, bulk transcriptomics, flow cytometry, cytokine and apoptosis assays","pmids":["41066163"],"confidence":"High","gaps":["In vivo validation of M28L variant in mouse brain not performed","Downstream effectors mediating apoptosis resistance not identified"]},{"year":2025,"claim":"A functional splicing variant (rs1071644-T) promoting nonsense-mediated decay of an aberrant PLCG2 isoform demonstrated a non-coding mechanism by which PLCγ2 levels are reduced to increase AD risk.","evidence":"Minigene splicing assay in BV-2 cells, NMD cycloheximide chase, HEK293 calcium assay, qRT-PCR in human brain","pmids":["41459197"],"confidence":"Medium","gaps":["Effect size of splicing variant on total PLCγ2 protein in microglia in vivo not quantified","Single lab, not yet independently replicated"]},{"year":null,"claim":"A high-resolution structure of autoinhibited PLCγ2 and the precise molecular mechanism by which it transitions to the active state remain undefined; furthermore, how PLCγ2 enzymatic activity is mechanistically linked to TREM2 transcriptional regulation in microglia is unknown.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of full-length autoinhibited PLCγ2","Biochemical intermediates connecting PLCγ2/Ca²⁺/IP3 to TREM2 promoter activity not identified","Cell-type-specific thresholds of PLCγ2 activity required for immune function (NK vs. B cell vs. microglia) not quantitatively defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,3,4,6,12]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,3,12]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[12,18]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[18]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,4,7,9,10,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,8,13,14,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,2,5,11,17]}],"complexes":[],"partners":["CSF1R","TREM2","NLRP3","RASA4"],"other_free_text":[]},"mechanistic_narrative":"PLCγ2 is a phospholipase C that hydrolyzes phosphatidylinositol 4,5-bisphosphate to generate IP3 and diacylglycerol, coupling receptor signaling to intracellular calcium release and activation of PKC, MAPK, NF-κB, and NFAT pathways. Its catalytic activity is restrained by autoinhibitory SH2 and C2 domain interactions; gain-of-function mutations disrupting this autoinhibition cause constitutive or temperature-sensitive hyperactivity that drives NLRP3 inflammasome activation and the PLAID/APLAID spectrum of immune dysregulation, while haploinsufficient loss-of-function variants impair NK cell calcium flux and cytotoxicity [PMID:22236196, PMID:23000145, PMID:25418813, PMID:38965708, PMID:37714437]. In microglia, PLCγ2 operates downstream of CSF1R and positively regulates TREM2 expression, inflammatory gene programs, and microglial association with amyloid plaques; the protective P522R hypermorph enhances antigen presentation and CD8⁺ T cell recruitment in Alzheimer's disease models, whereas loss-of-function variants phenocopy PLCG2 knockout with blunted inflammatory responses [PMID:40346446, PMID:35142046, PMID:41066163]. A splicing variant (rs1071644-T) promotes nonsense-mediated decay of an aberrant PLCG2 isoform, reducing functional enzyme levels and increasing Alzheimer's disease risk [PMID:41459197]."},"prefetch_data":{"uniprot":{"accession":"P16885","full_name":"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2","aliases":["Phosphoinositide phospholipase C-gamma-2","Phospholipase C-IV","PLC-IV","Phospholipase C-gamma-2","PLC-gamma-2"],"length_aa":1265,"mass_kda":147.9,"function":"The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. It is a crucial enzyme in transmembrane signaling","subcellular_location":"Membrane raft","url":"https://www.uniprot.org/uniprotkb/P16885/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PLCG2","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PLCG2","total_profiled":1310},"omim":[{"mim_id":"614878","title":"AUTOINFLAMMATION, ANTIBODY DEFICIENCY, AND IMMUNE DYSREGULATION; APLAID","url":"https://www.omim.org/entry/614878"},{"mim_id":"614468","title":"FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 3; FCAS3","url":"https://www.omim.org/entry/614468"},{"mim_id":"609201","title":"UBIQUITIN-ASSOCIATED AND SH3 DOMAIN-CONTAINING PROTEIN B; UBASH3B","url":"https://www.omim.org/entry/609201"},{"mim_id":"608462","title":"HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 8; HSCR8","url":"https://www.omim.org/entry/608462"},{"mim_id":"607360","title":"LACRITIN; LACRT","url":"https://www.omim.org/entry/607360"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":42.3}],"url":"https://www.proteinatlas.org/search/PLCG2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P16885","domains":[{"cath_id":"2.30.29.30","chopping":"8-136","consensus_level":"high","plddt":88.9508,"start":8,"end":136},{"cath_id":"1.10.238,1.10.238","chopping":"142-222","consensus_level":"medium","plddt":88.0731,"start":142,"end":222},{"cath_id":"1.10.238.10","chopping":"228-300","consensus_level":"medium","plddt":83.2322,"start":228,"end":300},{"cath_id":"3.20.20.190","chopping":"319-465_927-1045","consensus_level":"medium","plddt":91.0571,"start":319,"end":1045},{"cath_id":"2.30.29.30","chopping":"478-512_845-895","consensus_level":"high","plddt":80.0397,"start":478,"end":895},{"cath_id":"3.30.505.10","chopping":"533-630","consensus_level":"high","plddt":84.5373,"start":533,"end":630},{"cath_id":"3.30.505.10","chopping":"648-732","consensus_level":"high","plddt":84.8684,"start":648,"end":732},{"cath_id":"2.30.30.40","chopping":"775-827","consensus_level":"high","plddt":86.3191,"start":775,"end":827},{"cath_id":"2.60.40.150","chopping":"1055-1189","consensus_level":"medium","plddt":89.9519,"start":1055,"end":1189},{"cath_id":"1.10.287","chopping":"1194-1264","consensus_level":"medium","plddt":72.8723,"start":1194,"end":1264}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P16885","model_url":"https://alphafold.ebi.ac.uk/files/AF-P16885-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P16885-F1-predicted_aligned_error_v6.png","plddt_mean":83.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PLCG2","jax_strain_url":"https://www.jax.org/strain/search?query=PLCG2"},"sequence":{"accession":"P16885","fasta_url":"https://rest.uniprot.org/uniprotkb/P16885.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P16885/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P16885"}},"corpus_meta":[{"pmid":"28714976","id":"PMC_28714976","title":"Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.","date":"2017","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28714976","citation_count":770,"is_preprint":false},{"pmid":"22236196","id":"PMC_22236196","title":"Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions.","date":"2012","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22236196","citation_count":305,"is_preprint":false},{"pmid":"23000145","id":"PMC_23000145","title":"A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency.","date":"2012","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23000145","citation_count":268,"is_preprint":false},{"pmid":"30711010","id":"PMC_30711010","title":"Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph.","date":"2019","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30711010","citation_count":109,"is_preprint":false},{"pmid":"31243043","id":"PMC_31243043","title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31243043","citation_count":106,"is_preprint":false},{"pmid":"25349203","id":"PMC_25349203","title":"HLA-DQA1 and PLCG2 Are Candidate Risk Loci for Childhood-Onset Steroid-Sensitive Nephrotic Syndrome.","date":"2014","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/25349203","citation_count":105,"is_preprint":false},{"pmid":"31131421","id":"PMC_31131421","title":"A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.","date":"2019","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/31131421","citation_count":94,"is_preprint":false},{"pmid":"30326945","id":"PMC_30326945","title":"ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans.","date":"2018","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/30326945","citation_count":80,"is_preprint":false},{"pmid":"35180881","id":"PMC_35180881","title":"PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer's disease.","date":"2022","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35180881","citation_count":73,"is_preprint":false},{"pmid":"25418813","id":"PMC_25418813","title":"Connecting two pathways through Ca 2+ signaling: NLRP3 inflammasome activation induced by a hypermorphic PLCG2 mutation.","date":"2015","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/25418813","citation_count":66,"is_preprint":false},{"pmid":"36696464","id":"PMC_36696464","title":"BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/36696464","citation_count":64,"is_preprint":false},{"pmid":"30619256","id":"PMC_30619256","title":"Novel PLCG2 Mutation in a Patient With APLAID and Cutis Laxa.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30619256","citation_count":54,"is_preprint":false},{"pmid":"25760457","id":"PMC_25760457","title":"Distinct Cutaneous Manifestations and Cold-Induced Leukocyte Activation Associated With PLCG2 Mutations.","date":"2015","source":"JAMA dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/25760457","citation_count":45,"is_preprint":false},{"pmid":"32166339","id":"PMC_32166339","title":"PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment.","date":"2020","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/32166339","citation_count":45,"is_preprint":false},{"pmid":"37769878","id":"PMC_37769878","title":"PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37769878","citation_count":42,"is_preprint":false},{"pmid":"35142046","id":"PMC_35142046","title":"The P522R protective variant of PLCG2 promotes the expression of antigen presentation genes by human microglia in an Alzheimer's disease mouse model.","date":"2022","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/35142046","citation_count":40,"is_preprint":false},{"pmid":"32671674","id":"PMC_32671674","title":"Severe Autoinflammatory Manifestations and Antibody Deficiency Due to Novel Hypermorphic PLCG2 Mutations.","date":"2020","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32671674","citation_count":40,"is_preprint":false},{"pmid":"37031207","id":"PMC_37031207","title":"PLCG2 can exist in eccDNA and contribute to the metastasis of non-small cell lung cancer by regulating mitochondrial respiration.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37031207","citation_count":38,"is_preprint":false},{"pmid":"37955424","id":"PMC_37955424","title":"Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.","date":"2024","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/37955424","citation_count":37,"is_preprint":false},{"pmid":"32894242","id":"PMC_32894242","title":"Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes.","date":"2020","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/32894242","citation_count":31,"is_preprint":false},{"pmid":"33101590","id":"PMC_33101590","title":"Rh-CSF1 Attenuates Oxidative Stress and Neuronal Apoptosis via the CSF1R/PLCG2/PKA/UCP2 Signaling Pathway in a Rat Model of Neonatal HIE.","date":"2020","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/33101590","citation_count":30,"is_preprint":false},{"pmid":"31853824","id":"PMC_31853824","title":"A Germline Mutation in the C2 Domain of PLCγ2 Associated with Gain-of-Function Expands the Phenotype for PLCG2-Related Diseases.","date":"2019","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31853824","citation_count":29,"is_preprint":false},{"pmid":"29538758","id":"PMC_29538758","title":"Using genes to triangulate the pathophysiology of granulomatous autoinflammatory disease: NOD2, PLCG2 and LACC1.","date":"2018","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29538758","citation_count":26,"is_preprint":false},{"pmid":"32522286","id":"PMC_32522286","title":"Rh-CSF1 attenuates neuroinflammation via the CSF1R/PLCG2/PKCε pathway in a rat model of neonatal HIE.","date":"2020","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32522286","citation_count":24,"is_preprint":false},{"pmid":"31549850","id":"PMC_31549850","title":"PLCG2 promotes hepatocyte proliferation in vitro via NF-κB and ERK pathway by targeting bcl2, myc and ccnd1.","date":"2019","source":"Artificial cells, nanomedicine, and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31549850","citation_count":20,"is_preprint":false},{"pmid":"35813947","id":"PMC_35813947","title":"Plcg2 Interacts With High Fat/High Sugar Diet to Accelerate Alzheimer's Disease-Relevant Phenotypes in Mice.","date":"2022","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35813947","citation_count":19,"is_preprint":false},{"pmid":"39494327","id":"PMC_39494327","title":"Targeting PLCG2 Suppresses Tumor Progression, Orchestrates the Tumor Immune Microenvironment and Potentiates Immune Checkpoint Blockade Therapy for Colorectal Cancer.","date":"2024","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39494327","citation_count":18,"is_preprint":false},{"pmid":"33725976","id":"PMC_33725976","title":"PLCG2 as a potential indicator of tumor microenvironment remodeling in soft tissue sarcoma.","date":"2021","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33725976","citation_count":18,"is_preprint":false},{"pmid":"36530083","id":"PMC_36530083","title":"Novel Genetic Variants in TP37, PIK3R1, CALM1, and PLCG2 of the Neurotrophin Signaling Pathway Are Associated with the Progression from Mild Cognitive Impairment to Alzheimer's Disease.","date":"2023","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/36530083","citation_count":16,"is_preprint":false},{"pmid":"7774933","id":"PMC_7774933","title":"Phospholipase C gamma-2 (Plcg2) and phospholipase C gamma-1 (Plcg1) map to distinct regions in the human and mouse genomes.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7774933","citation_count":14,"is_preprint":false},{"pmid":"39108206","id":"PMC_39108206","title":"Methyltransferase DNMT3B promotes colorectal cancer cell proliferation by inhibiting PLCG2.","date":"2024","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/39108206","citation_count":11,"is_preprint":false},{"pmid":"26966907","id":"PMC_26966907","title":"A Gain-Of-Function Mutation in the Plcg2 Gene Protects Mice from Helicobacter felis-Induced Gastric MALT Lymphoma.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26966907","citation_count":10,"is_preprint":false},{"pmid":"35955991","id":"PMC_35955991","title":"Variant in the PLCG2 Gene May Cause a Phenotypic Overlap of APLAID/PLAID: Case Series and Literature Review.","date":"2022","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35955991","citation_count":10,"is_preprint":false},{"pmid":"32014489","id":"PMC_32014489","title":"A new report of autoinflammation and PLCG2-associated antibody deficiency and immune dysregulation (APLAID) with a homozygous pattern from Iran.","date":"2020","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32014489","citation_count":10,"is_preprint":false},{"pmid":"31560769","id":"PMC_31560769","title":"Pathway Analysis Integrating Genome-Wide and Functional Data Identifies PLCG2 as a Candidate Gene for Age-Related Macular Degeneration.","date":"2019","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/31560769","citation_count":9,"is_preprint":false},{"pmid":"33936634","id":"PMC_33936634","title":"Four diseases, PLAID, APLAID, FCAS3 and CVID and one gene (PHOSPHOLIPASE C, GAMMA-2; PLCG2): Striking clinical phenotypic overlap and difference.","date":"2021","source":"Clinical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/33936634","citation_count":9,"is_preprint":false},{"pmid":"37714437","id":"PMC_37714437","title":"Human PLCG2 haploinsufficiency results in a novel natural killer cell immunodeficiency.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37714437","citation_count":8,"is_preprint":false},{"pmid":"40346446","id":"PMC_40346446","title":"PLCG2 modulates TREM2 expression and signaling in response to Alzheimer's disease pathology.","date":"2025","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/40346446","citation_count":7,"is_preprint":false},{"pmid":"39487477","id":"PMC_39487477","title":"Alzheimer's disease-associated protective variant Plcg2-P522R modulates peripheral macrophage function in a sex-dimorphic manner.","date":"2024","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/39487477","citation_count":6,"is_preprint":false},{"pmid":"34768012","id":"PMC_34768012","title":"A novel likely pathogenic PLCG2 variant in a patient with a recurrent skin blistering disease and B-cell lymphopenia.","date":"2021","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34768012","citation_count":6,"is_preprint":false},{"pmid":"39863641","id":"PMC_39863641","title":"Overexpression of PLCG2 and TMEM38A inhibit tumor progression in clear cell renal cell carcinoma.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39863641","citation_count":5,"is_preprint":false},{"pmid":"36776842","id":"PMC_36776842","title":"Clinical and immunological features of an APLAID patient caused by a novel mutation in PLCG2.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36776842","citation_count":4,"is_preprint":false},{"pmid":"39614428","id":"PMC_39614428","title":"The PLCG2 Inhibits Tumor Progression and Mediates Angiogenesis by VEGF Signaling Pathway in Clear Cell Renal Cell Carcinoma.","date":"2024","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/39614428","citation_count":4,"is_preprint":false},{"pmid":"39667583","id":"PMC_39667583","title":"Splice site and de novo variants can cause PLCG2-associated immune dysregulation with cold urticaria.","date":"2024","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39667583","citation_count":2,"is_preprint":false},{"pmid":"27323081","id":"PMC_27323081","title":"Construction of recombinant adenovirus Ad-rat PLCg2-shRNA and successful suppression of PLCg2 expression in BRL-3A cells.","date":"2016","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/27323081","citation_count":2,"is_preprint":false},{"pmid":"31955222","id":"PMC_31955222","title":"Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.","date":"2020","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/31955222","citation_count":2,"is_preprint":false},{"pmid":"38965708","id":"PMC_38965708","title":"Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF Inhibitor.","date":"2024","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/38965708","citation_count":1,"is_preprint":false},{"pmid":"41066163","id":"PMC_41066163","title":"Alzheimer's disease-associated PLCG2 variants alter microglial state and function in human induced pluripotent stem cell-derived microglia-like cells.","date":"2025","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/41066163","citation_count":1,"is_preprint":false},{"pmid":"39197752","id":"PMC_39197752","title":"PLCG2 variants in cherubism.","date":"2024","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39197752","citation_count":1,"is_preprint":false},{"pmid":"33089525","id":"PMC_33089525","title":"A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.","date":"2020","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/33089525","citation_count":1,"is_preprint":false},{"pmid":"40170866","id":"PMC_40170866","title":"Case Report: de novo in-frame deletion in PLCG2 gene: a case report of B-cell lymphopenia, pulmonary bullae, and cutis laxa.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40170866","citation_count":1,"is_preprint":false},{"pmid":"40585241","id":"PMC_40585241","title":"Genetics of PLCG2 expression and splicing relative to Alzheimer's disease risk.","date":"2025","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/40585241","citation_count":0,"is_preprint":false},{"pmid":"41459197","id":"PMC_41459197","title":"Genetics of PLCG2 expression and splicing relative to Alzheimer's disease risk.","date":"2025","source":"Molecular neurodegeneration advances","url":"https://pubmed.ncbi.nlm.nih.gov/41459197","citation_count":0,"is_preprint":false},{"pmid":"41507916","id":"PMC_41507916","title":"PLCG2 across human disease: genetic variants, signaling mechanisms, and clinical implications.","date":"2026","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41507916","citation_count":0,"is_preprint":false},{"pmid":"41537131","id":"PMC_41537131","title":"Early-onset bibasilar emphysema in a patient with PLCG2-related immune dysregulation.","date":"2025","source":"Respiratory medicine case reports","url":"https://pubmed.ncbi.nlm.nih.gov/41537131","citation_count":0,"is_preprint":false},{"pmid":"38562814","id":"PMC_38562814","title":"Splice site and de novo mutations can cause mixed dominant negative/gain of function PLCG2-associated immune dysregulation with cold urticaria (CU-PLAID).","date":"2024","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38562814","citation_count":0,"is_preprint":false},{"pmid":"41928929","id":"PMC_41928929","title":"Non-microglial downregulation of PLCG2 impairs synaptic function and elicits Alzheimer disease-related hallmarks.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41928929","citation_count":0,"is_preprint":false},{"pmid":"41176779","id":"PMC_41176779","title":"PLCG2 promotes cell survival and mitophagy of small cell lung cancer via regulating VCP.","date":"2025","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/41176779","citation_count":0,"is_preprint":false},{"pmid":"41888907","id":"PMC_41888907","title":"PLCG2 signaling and genetic resilience in Alzheimer's disease.","date":"2026","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/41888907","citation_count":0,"is_preprint":false},{"pmid":"41620758","id":"PMC_41620758","title":"Protective PLCG2 variants associate with a delayed onset of Alzheimer's disease among heterozygous APOE ε4 carriers.","date":"2026","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/41620758","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.09.22.25336304","title":"The protective <i>PLCG2</i> variants delay Alzheimer’s disease onset age in <i>APOE ε</i>4 carriers","date":"2025-09-25","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.22.25336304","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.11.05.25339630","title":"Cerebrospinal fluid transcriptional immune pathways linked to survival in HIV-associated tuberculous meningitis","date":"2025-11-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.05.25339630","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.07.647573","title":"PLCγ2 Controls Neutrophil Sensitivity through Calcium Oscillation and Gates Chemoattractant Concentration Range for Chemotaxis","date":"2025-04-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.07.647573","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.11.659052","title":"A collection of patient-derived intestinal organoid lines reveals epithelial pheno-types associated with genetic drivers of pediatric inflammatory bowel disease","date":"2025-06-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.11.659052","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.26.24316189","title":"Integrating explainable machine learning and transcriptomics data reveals cell-type specific immune signatures underlying macular degeneration","date":"2024-10-27","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.26.24316189","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.05.28.596275","title":"Alzheimer’s disease-associated protective variant Plcg2-P522R modulates peripheral macrophage function in a sex-dimorphic manner","date":"2024-06-01","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.28.596275","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38580,"output_tokens":5463,"usd":0.098842},"stage2":{"model":"claude-opus-4-6","input_tokens":9069,"output_tokens":4137,"usd":0.223155},"total_usd":0.321997,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"In-frame genomic deletions within a region encoding an autoinhibitory domain of PLCγ2 result in protein products with constitutive phospholipase activity; these deletion proteins show diminished cellular signaling at 37°C but enhanced signaling at subphysiologic temperatures, establishing a temperature-sensitive gain-of-function mechanism underlying PLAID.\",\n      \"method\": \"Genomic sequencing, cDNA sequencing, enzymatic assays, flow cytometry, lymphocyte stimulation assays\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (sequencing, enzymatic assay, cellular signaling) in a single rigorous study with functional validation\",\n      \"pmids\": [\"22236196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The p.Ser707Tyr substitution in the autoinhibitory SH2 domain of PLCγ2 causes a hypermorphic gain-of-function, leading to enhanced PLCγ2 activity and increased intracellular signaling at physiological temperatures, distinct from the cold-sensitive PLAID deletions.\",\n      \"method\": \"Whole-exome sequencing, overexpression of mutant protein in heterologous cells, ex vivo leukocyte signaling assays\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal functional assays (overexpression + ex vivo) with multiple orthogonal methods\",\n      \"pmids\": [\"23000145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The APLAID-causing hypermorphic PLCγ2 p.Ser707Tyr mutation causes elevated basal intracellular Ca2+ and enhanced Ca2+ flux, which activates the NLRP3 inflammasome, linking PLCγ2-mediated Ca2+ signaling to IL-1β secretion and sterile inflammation; this effect was attenuated by PLC inhibitors, intracellular Ca2+ blockers, or adenylate cyclase activators.\",\n      \"method\": \"Western blotting (inflammasome activation), FLIPR calcium flux assay, pharmacological inhibition in patient PBMCs\",\n      \"journal\": \"Arthritis & rheumatology (Hoboken, N.J.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, functional rescue experiments in patient-derived cells\",\n      \"pmids\": [\"25418813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The PLCG2 p.P522R (Pro522Arg) variant is a functional hypermorph that weakly increases PLCγ2 enzymatic activity, as demonstrated by radioactive phospholipase assay, IP-One ELISA, and calcium assays in heterologous COS7 and HEK293T cells.\",\n      \"method\": \"Radioactive enzymatic assay, IP-One ELISA, calcium assay in transfected COS7 and HEK293T cells\",\n      \"journal\": \"Alzheimer's research & therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — three orthogonal in vitro assays in a single study with rigorous controls\",\n      \"pmids\": [\"30711010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A novel gain-of-function mutation in the C2 domain of PLCγ2 (p.Met1141Lys) causes platelet hyper-reactivity, increased BCR-triggered calcium influx and ERK phosphorylation, and enhanced BCR-triggered influx of external calcium in a PLCγ2-knockout DT40 cell line, demonstrating that the C2 domain can regulate PLCγ2 autoinhibition.\",\n      \"method\": \"Flow cytometry (calcium flux, ERK phosphorylation), DT40 knockout cell overexpression system, platelet function assay\",\n      \"journal\": \"Journal of clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays in knockout reconstitution system, single lab\",\n      \"pmids\": [\"31853824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Novel APLAID-causing PLCG2 variants (p.Ala708Pro and p.Leu845_Leu848del) activate the NLRP3 inflammasome through the alternative pathway (not the canonical pathway), as demonstrated by ex vivo calcium responses of patient B cells and in vitro PLC activity assays.\",\n      \"method\": \"Ex vivo B cell calcium flux assay, in vitro PLC activity assay, inflammasome pathway analysis\",\n      \"journal\": \"Journal of clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional validation with multiple assays, single lab\",\n      \"pmids\": [\"32671674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The novel APLAID-causing p.Leu848Pro mutation in PLCγ2 (located in the cSH2 domain) leads to increased basal and EGF-stimulated PLCγ2 activity in vitro, expanding the spectrum of gain-of-function PLCG2 mutations affecting the autoinhibitory domain.\",\n      \"method\": \"In vitro PLC activity assay, whole blood cytokine assays\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro activity assay with functional follow-up, single lab\",\n      \"pmids\": [\"30619256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PLCG2 variants functionally classified as gain-of-function (GOF) or monoallelic loss-of-function (LOF) alter B-cell activation (BCR-induced calcium flux and ERK phosphorylation) in opposite directions; monoallelic LOF variants define a new class associated with humoral immune deficiency, autoinflammation, herpesvirus susceptibility, and NK cell dysfunction.\",\n      \"method\": \"Mutagenesis of EGFP-PLCG2 plasmid, overexpression in Plcg2-deficient DT40 B cells, flow cytometry (calcium flux, ERK phosphorylation), primary patient cell stimulation\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic functional classification using knockout reconstitution + primary cells, multiple variants tested\",\n      \"pmids\": [\"37769878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PLCγ2 haploinsufficiency (loss-of-function heterozygous PLCG2 variants) impairs NK cell calcium flux and cytotoxicity while preserving B-cell function, establishing a distinct NK cell immunodeficiency syndrome; this phenotype was recapitulated in Plcg2+/- mice.\",\n      \"method\": \"Whole-exome sequencing, mass cytometry, functional assays (calcium flux, cytotoxicity), Plcg2+/- mouse model\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human and mouse data with multiple orthogonal functional assays, phenotype replicated in mouse model\",\n      \"pmids\": [\"37714437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Rh-CSF1 activates a CSF1R/PLCG2/PKA/UCP2 signaling pathway in neonatal rat brain after hypoxic-ischemic injury, reducing oxidative stress and neuronal apoptosis; pharmacological inhibition of PLCG2 with U73122 abolished the neuroprotective effects of rh-CSF1.\",\n      \"method\": \"Western blot (p-PLCG2, p-PKA, UCP2), pharmacological inhibition (BLZ945, U73122), immunofluorescence, behavioral tests, TUNEL/Fluoro-Jade staining in rat HI model\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis with pathway readout, in vivo model, single lab\",\n      \"pmids\": [\"33101590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Rh-CSF1 activates a CSF1R/PLCG2/PKCε/CREB signaling axis that attenuates neuroinflammation after hypoxic-ischemia; inhibition of PLCG2 with U73122 blocked the anti-inflammatory effects including IL-1β and TNF-α downregulation.\",\n      \"method\": \"Western blot (p-PLCG2, p-PKCε, p-CREB), pharmacological inhibition, immunofluorescence, rat HI model\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis establishing pathway position, in vivo model, single lab\",\n      \"pmids\": [\"32522286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PLCG2 deficiency in 5xFAD mice reduces TREM2 expression and impairs microglial association with amyloid-beta plaques, while TREM2 deficiency increases PLCG2 expression; human transcriptomics confirmed a positive correlation between PLCG2 and TREM2 expression independent of pathological scores, indicating PLCG2 acts upstream to regulate TREM2-mediated immune responses.\",\n      \"method\": \"5xFAD x PLCG2-KO x TREM2-KO mouse crosses, RNA-sequencing (mouse and human bulk), immunostaining\",\n      \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with orthogonal human and mouse data, double-KO cross design\",\n      \"pmids\": [\"40346446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The novel PLCγ2 D993Y variant (APLAID-associated) disrupts the interaction between the catalytic and autoinhibitory domains of PLCγ2, causing autoactivation with heightened PLCγ2 phosphorylation, elevated IP3 production, increased intracellular Ca2+ release, and activation of MAPK, NF-κB, and NFAT signaling pathways.\",\n      \"method\": \"Immunoblotting, luciferase assay (NF-κB/NFAT), inositol monophosphate ELISA, calcium flux assay, immunoprecipitation (domain interaction), overexpression in HEK293T/COS-7/THP-1 KO cells\",\n      \"journal\": \"Arthritis & rheumatology (Hoboken, N.J.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal mechanistic assays including domain interaction by Co-IP and functional reconstitution in KO cells\",\n      \"pmids\": [\"38965708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The protective PLCG2-P522R variant in human iPSC-derived microglia transplanted into chimeric AD mice induces significant upregulation of HLA expression and antigen presentation, chemokine signaling, and T cell proliferation pathways, and promotes CD8+ T cell recruitment to the brain.\",\n      \"method\": \"Chimeric mouse model with iPSC-microglia transplantation, single-cell and bulk RNA sequencing, histological analysis\",\n      \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — iPSC-microglia chimeric mouse model with scRNA-seq, strong functional readout\",\n      \"pmids\": [\"35142046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PLCG2 expression in microglia is induced by amyloid plaques in a disease progression-dependent manner in 5xFAD mice, and PLCG2 co-expression network analysis links PLCG2 to inflammatory pathways including NF-κB signaling and response to LPS; inactivation of Plcg2 in mice altered immune-related gene expression without changing microglial cell coverage or morphology.\",\n      \"method\": \"Bulk RNA-seq (human AD brain, 5xFAD mice), single-cell RNA-seq, microglia depletion, immunostaining, differential expression analysis in Plcg2-inactivated mice\",\n      \"journal\": \"Genome medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple transcriptomic datasets + mouse model with KO validation, single primary analysis\",\n      \"pmids\": [\"35180881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Risk-conferring PLCG2-M28L microglia (iPSC-derived) share transcriptomic similarity with PLCG2-KO microglia, showing reduced TREM2 expression, blunted inflammatory responses, and increased proliferation/cell death, whereas protective PLCG2-P522R microglia show elevated cytokine secretion after LPS and resistance to apoptosis, demonstrating that PLCG2 variants bidirectionally modulate microglial immune state and function.\",\n      \"method\": \"iPSC-derived microglia with isogenic PLCG2 variants (P522R, M28L, KO), bulk transcriptomics, flow cytometry, cytokine assays, apoptosis assays\",\n      \"journal\": \"Alzheimer's & dementia : the journal of the Alzheimer's Association\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isogenic iPSC model with multiple variants, multiple orthogonal functional assays\",\n      \"pmids\": [\"41066163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The DNMT3B methyltransferase inhibits PLCG2 transcription by methylating the PLCG2 promoter region in colorectal cancer cells; overexpression of PLCG2 suppresses colorectal cancer xenograft tumor growth in vivo.\",\n      \"method\": \"Methylation-specific PCR (MSP), bisulfite-sequencing PCR (BSP), DNMT3B overexpression/knockdown, PLCG2 overexpression, xenograft mouse model\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct epigenetic mechanism (MSP/BSP) + in vivo functional validation, single lab\",\n      \"pmids\": [\"39108206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A novel PLCG2 mRNA isoform (D65-PLCG2) lacking 65 bp from exon 28 is susceptible to nonsense-mediated decay and lacks Ca2+ responsiveness (demonstrated in transfected HEK293 cells); the rs1071644-T allele promotes increased exon 28 skipping via a functional splicing variant, thereby reducing functional PLCγ2 and increasing AD risk.\",\n      \"method\": \"Minigene splicing assay in BV-2 microglial cells, cycloheximide NMD assay, HEK293 transfection calcium assay, qRT-PCR in human brain/buffy coat\",\n      \"journal\": \"Molecular neurodegeneration advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — functional minigene assay + calcium assay + NMD validation, single lab\",\n      \"pmids\": [\"41459197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PLCγ2 mediates spontaneous calcium oscillation and chemoattractant-induced calcium response in neutrophils; PLCγ2 knockdown impairs spontaneous Ca2+ oscillation, reduces membrane targeting of CAPRI (a RasGAP), causes increased Ras/PI3Kγ activation and actin polymerization, and alters the chemoattractant concentration range for neutrophil chemotaxis.\",\n      \"method\": \"plcg2 knockdown neutrophils, calcium imaging, membrane targeting assays, PI3K activity, actin polymerization assays, chemotaxis assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with multiple pathway readouts; preprint, not peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.04.07.647573\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PLCG2 in colorectal cancer cells promotes proliferation, invasion, metastasis, EMT, and cell cycle progression while inhibiting apoptosis via Akt-mTOR pathway activation; PLCG2 knockdown also suppresses CD8+ T cell infiltration, promotes Treg infiltration, and upregulates PD-1/PD-L1 expression, potentiating immune checkpoint blockade therapy.\",\n      \"method\": \"RNA-seq, western blotting, qRT-PCR, in vivo xenograft models, flow cytometry, multiplex immunohistochemistry\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo loss-of-function with defined pathway (Akt-mTOR) and immune microenvironment readouts, single lab\",\n      \"pmids\": [\"39494327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Splice site mutations and de novo deletions in PLCG2 can cause in-frame exon skipping (e.g., loss of exons 18-19 or 19-22); overexpression of these deletion transcripts in Plcg2-deficient DT40 cells failed to phosphorylate ERK in response to BCR crosslinking, confirming dominant-negative function at physiological temperature.\",\n      \"method\": \"Full-length PLCG2 cDNA RNA sequencing, whole genome sequencing, DT40 Plcg2-KO overexpression, flow cytometry (ERK phosphorylation)\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockout reconstitution system with BCR signaling readout, validated with primary patient samples\",\n      \"pmids\": [\"39667583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The PLCG2 gene was mapped to chromosome 16q22-qter in humans and to the central region of mouse chromosome 8, establishing that PLCG2 and PLCG1 are members of a dispersed gene family mapping to distinct chromosomal regions.\",\n      \"method\": \"Interspecific backcross mapping (mouse), rodent/human somatic cell hybrid panel (human)\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal mapping with two orthogonal approaches\",\n      \"pmids\": [\"7774933\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PLCγ2 is a phospholipase C enzyme that hydrolyzes phosphatidylinositol 4,5-bisphosphate to generate IP3 and diacylglycerol, thereby releasing intracellular Ca2+ and activating downstream signaling (PKC, MAPK, NF-κB, NFAT); its activity is kept in check by an autoinhibitory SH2 domain, such that in-frame deletions or missense mutations disrupting this domain cause gain-of-function (constitutive or temperature-sensitive activity) driving PLAID/APLAID immune dysregulation, whereas haploinsufficiency impairs NK cell calcium flux and cytotoxicity; in microglia, PLCγ2 acts downstream of CSF1R and upstream of TREM2 to regulate microglial phagocytic and inflammatory responses to amyloid pathology, and in neutrophils it controls spontaneous calcium oscillation, membrane targeting of the RasGAP CAPRI, and chemotaxis sensitivity.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PLCγ2 is a phospholipase C that hydrolyzes phosphatidylinositol 4,5-bisphosphate to generate IP3 and diacylglycerol, coupling receptor signaling to intracellular calcium release and activation of PKC, MAPK, NF-κB, and NFAT pathways. Its catalytic activity is restrained by autoinhibitory SH2 and C2 domain interactions; gain-of-function mutations disrupting this autoinhibition cause constitutive or temperature-sensitive hyperactivity that drives NLRP3 inflammasome activation and the PLAID/APLAID spectrum of immune dysregulation, while haploinsufficient loss-of-function variants impair NK cell calcium flux and cytotoxicity [PMID:22236196, PMID:23000145, PMID:25418813, PMID:38965708, PMID:37714437]. In microglia, PLCγ2 operates downstream of CSF1R and positively regulates TREM2 expression, inflammatory gene programs, and microglial association with amyloid plaques; the protective P522R hypermorph enhances antigen presentation and CD8⁺ T cell recruitment in Alzheimer's disease models, whereas loss-of-function variants phenocopy PLCG2 knockout with blunted inflammatory responses [PMID:40346446, PMID:35142046, PMID:41066163]. A splicing variant (rs1071644-T) promotes nonsense-mediated decay of an aberrant PLCG2 isoform, reducing functional enzyme levels and increasing Alzheimer's disease risk [PMID:41459197].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing that PLCG2 is a distinct gene family member at chromosome 16q22 resolved its genomic identity relative to PLCG1 and enabled subsequent mutation-phenotype studies.\",\n      \"evidence\": \"Interspecific backcross mapping and somatic cell hybrid panel analysis in mouse and human\",\n      \"pmids\": [\"7774933\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional data from mapping alone\", \"Expression pattern across tissues not determined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Discovery that in-frame deletions in the autoinhibitory cSH2 domain cause constitutive phospholipase activity with temperature-sensitive signaling established the first molecular mechanism for PLAID and identified the autoinhibitory domain as the key regulatory element of PLCγ2.\",\n      \"evidence\": \"Genomic/cDNA sequencing, enzymatic assays, and lymphocyte signaling in PLAID patient cells\",\n      \"pmids\": [\"22236196\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of temperature sensitivity not resolved\", \"Whether other domain mutations can cause similar phenotypes was unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of the p.Ser707Tyr missense mutation as a constitutive gain-of-function at physiological temperature distinguished APLAID from the cold-sensitive PLAID mechanism, showing that different classes of autoinhibitory disruption produce distinct clinical syndromes.\",\n      \"evidence\": \"Whole-exome sequencing, overexpression in heterologous cells, and ex vivo leukocyte signaling\",\n      \"pmids\": [\"23000145\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism by which S707Y disrupts autoinhibition not defined\", \"Downstream inflammatory consequences not yet explored\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linking the PLCγ2 S707Y gain-of-function to NLRP3 inflammasome activation via elevated basal Ca²⁺ established the signaling chain from PLCγ2 hyperactivity to IL-1β-mediated sterile inflammation, explaining APLAID pathogenesis.\",\n      \"evidence\": \"FLIPR calcium flux, inflammasome western blot, and pharmacological rescue (PLC inhibitors, Ca²⁺ blockers) in patient PBMCs\",\n      \"pmids\": [\"25418813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether canonical vs. alternative inflammasome pathway is engaged was unresolved\", \"Contribution of DAG/PKC arm to inflammasome activation not dissected\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Expanding the mutational spectrum to include p.Leu848Pro in the cSH2 domain confirmed that multiple positions within the autoinhibitory region regulate PLCγ2 basal activity.\",\n      \"evidence\": \"In vitro PLC activity assay and whole blood cytokine assays\",\n      \"pmids\": [\"30619256\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only a single variant tested\", \"No structural modeling of how L848P disrupts autoinhibition\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating that the AD-protective P522R variant is a weak enzymatic hypermorph connected PLCγ2 gain-of-function to neuroprotection and positioned PLCγ2 as a modulator of microglial function in neurodegeneration.\",\n      \"evidence\": \"Radioactive phospholipase assay, IP-One ELISA, and calcium assay in transfected COS7/HEK293T cells\",\n      \"pmids\": [\"30711010\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of P522R-mediated neuroprotection in microglia not yet characterized\", \"Whether enzymatic hyperactivity alone explains the protective effect was unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Discovery that the C2 domain mutation p.Met1141Lys causes gain-of-function revealed a second autoinhibitory surface beyond the cSH2 domain, broadening understanding of PLCγ2 regulation.\",\n      \"evidence\": \"Calcium flux and ERK phosphorylation in PLCγ2-knockout DT40 cell reconstitution system\",\n      \"pmids\": [\"31853824\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only one C2-domain variant tested\", \"No direct biophysical evidence of C2–catalytic domain interaction\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placing PLCγ2 downstream of CSF1R in a CSF1R/PLCγ2/PKA/UCP2 and CSF1R/PLCγ2/PKCε/CREB signaling axis in neonatal brain defined PLCγ2's role in anti-oxidative and anti-inflammatory neuroprotection.\",\n      \"evidence\": \"Pharmacological epistasis (U73122, BLZ945) with western blot pathway readouts in rat hypoxic-ischemic injury model\",\n      \"pmids\": [\"33101590\", \"32522286\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reliance on U73122, a non-specific PLC inhibitor\", \"No genetic confirmation in PLCγ2-deficient animals\", \"Single lab, single model system\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showing that novel APLAID variants activate the alternative (not canonical) NLRP3 inflammasome pathway refined the inflammatory mechanism downstream of PLCγ2 hyperactivity.\",\n      \"evidence\": \"Ex vivo B cell calcium flux and in vitro PLC activity assays in patient cells\",\n      \"pmids\": [\"32671674\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Distinction between canonical and alternative inflammasome activation requires further biochemical dissection\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating that P522R microglia transplanted into AD mice upregulate HLA, antigen presentation, and CD8⁺ T cell recruitment established a cell-autonomous immune-enhancing mechanism for the protective PLCγ2 variant in Alzheimer's disease.\",\n      \"evidence\": \"iPSC-derived microglia chimeric mouse model with scRNA-seq and histological analysis\",\n      \"pmids\": [\"35142046\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether enhanced antigen presentation is sufficient for neuroprotection not tested\", \"Chimeric model may not fully recapitulate endogenous microglial function\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showing that PLCγ2 expression in microglia is induced by amyloid plaques in a progression-dependent manner and that inactivation alters immune gene expression linked PLCγ2 to disease-stage-specific microglial inflammatory programs.\",\n      \"evidence\": \"Bulk and single-cell RNA-seq in human AD brain and 5xFAD mice, Plcg2-inactivated mouse model\",\n      \"pmids\": [\"35180881\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptomic changes without demonstration of phagocytic or clearance phenotype\", \"Mechanism of plaque-dependent induction of PLCG2 not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Systematic functional classification of GOF and LOF PLCG2 variants in DT40 reconstitution and patient cells revealed that monoallelic LOF defines a new class of immune deficiency, establishing a bidirectional genotype-phenotype framework.\",\n      \"evidence\": \"Mutagenesis, Plcg2-deficient DT40 overexpression, flow cytometry for calcium/ERK, primary patient cell stimulation\",\n      \"pmids\": [\"37769878\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Not all variants tested in primary human cells\", \"In vivo consequences of LOF variants in adaptive immunity not fully explored\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Establishing that PLCγ2 haploinsufficiency selectively impairs NK cell calcium flux and cytotoxicity (but not B cell function) identified a cell-type-specific dependency and a distinct NK cell immunodeficiency phenotype, replicated in Plcg2⁺/⁻ mice.\",\n      \"evidence\": \"Whole-exome sequencing, mass cytometry, functional assays, Plcg2⁺/⁻ mouse model\",\n      \"pmids\": [\"37714437\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of selective NK cell vulnerability versus B cell resilience not explained\", \"Threshold of PLCγ2 activity required for NK function unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Structural-functional analysis of the D993Y variant demonstrated direct disruption of catalytic-autoinhibitory domain interaction, causing autoactivation of IP3/Ca²⁺/MAPK/NF-κB/NFAT, providing the most detailed intramolecular mechanism for PLCγ2 autoinhibition relief.\",\n      \"evidence\": \"Co-IP of domain interactions, IP1 ELISA, calcium flux, NF-κB/NFAT luciferase reporters in THP-1 KO and HEK293T cells\",\n      \"pmids\": [\"38965708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of autoinhibited vs. activated PLCγ2\", \"Mechanism applicable to all GOF variants not confirmed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Splice-site mutations causing in-frame exon skipping produced dominant-negative PLCγ2 proteins that failed to activate ERK upon BCR crosslinking, expanding the LOF variant class beyond point mutations.\",\n      \"evidence\": \"Full-length cDNA RNA-seq, WGS, DT40 Plcg2-KO reconstitution with flow cytometry\",\n      \"pmids\": [\"39667583\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dominant-negative mechanism (e.g., competition for scaffolding) not biochemically defined\", \"Limited number of splice variants tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Genetic epistasis in 5xFAD mice showed PLCγ2 deficiency reduces TREM2 expression and microglial plaque association while TREM2 deficiency increases PLCγ2, establishing PLCγ2 as an upstream positive regulator of TREM2 with a feedback loop.\",\n      \"evidence\": \"5xFAD × PLCG2-KO × TREM2-KO crosses, RNA-seq (mouse and human), immunostaining\",\n      \"pmids\": [\"40346446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical mechanism linking PLCγ2 activity to TREM2 transcription unknown\", \"Whether the feedback loop operates in non-AD contexts not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Isogenic iPSC-microglia carrying P522R versus M28L versus KO demonstrated bidirectional modulation of microglial immune state: P522R enhances cytokine secretion and resists apoptosis while M28L/KO show blunted responses and reduced TREM2, consolidating the variant-function spectrum in a disease-relevant cell type.\",\n      \"evidence\": \"Isogenic iPSC-derived microglia, bulk transcriptomics, flow cytometry, cytokine and apoptosis assays\",\n      \"pmids\": [\"41066163\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo validation of M28L variant in mouse brain not performed\", \"Downstream effectors mediating apoptosis resistance not identified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A functional splicing variant (rs1071644-T) promoting nonsense-mediated decay of an aberrant PLCG2 isoform demonstrated a non-coding mechanism by which PLCγ2 levels are reduced to increase AD risk.\",\n      \"evidence\": \"Minigene splicing assay in BV-2 cells, NMD cycloheximide chase, HEK293 calcium assay, qRT-PCR in human brain\",\n      \"pmids\": [\"41459197\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Effect size of splicing variant on total PLCγ2 protein in microglia in vivo not quantified\", \"Single lab, not yet independently replicated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution structure of autoinhibited PLCγ2 and the precise molecular mechanism by which it transitions to the active state remain undefined; furthermore, how PLCγ2 enzymatic activity is mechanistically linked to TREM2 transcriptional regulation in microglia is unknown.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of full-length autoinhibited PLCγ2\", \"Biochemical intermediates connecting PLCγ2/Ca²⁺/IP3 to TREM2 promoter activity not identified\", \"Cell-type-specific thresholds of PLCγ2 activity required for immune function (NK vs. B cell vs. microglia) not quantitatively defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 3, 4, 6, 12]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 3, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [12, 18]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 4, 7, 9, 10, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 8, 13, 14, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 2, 5, 11, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CSF1R\",\n      \"TREM2\",\n      \"NLRP3\",\n      \"RASA4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}